Plain-English translation of NCT02139020 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are collecting blood samples from patients with squamous cell carcinoma of the head and neck who are being treated with targeted therapies like cetuximab. By studying these blood samples over time, the research team hopes to identify biomarkers—measurable signs in the blood—that can predict whether a patient will respond well to treatment or develop resistance to it.
Some patients respond very well to targeted cancer therapies, while others do not. This study aims to find early warning signs in the blood that could help doctors predict treatment success and potentially adjust care plans before resistance develops.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have blood samples taken at three key points: before your treatment starts, while you are receiving treatment, and if your cancer progresses. These blood draws will happen during your regular cancer care visits, so there are no additional hospital trips required. The researchers will use your samples to study how your body responds to the medication over time.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Belgium
Sponsor
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Enrollment target
~400 participants
Started
February 2013
Primary completion
January 2033
Age range
18 Years and older
Last updated on clinicaltrials.gov in December 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jean-Pascal Machiels, MD, PhD
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.